The use of proton pump inhibitors (PPIs) has been linked to hypomagnesaemia in a number of case reports. In 2012, the MHRA issued a Drug Safety Update advising measurement of magnesium before starting PPI treatment, and repeat measurements periodically during prolonged treatment, especially in those taking other drugs that may cause hypomagnesaemia. However, comparative studies published subsequently have been conflicting. This meta-analysis therefore aimed to re-examine the risk of hypomagnesaemia with PPI use.
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Nine studies (115,455 patients) were included in the meta-analysis. In patients receiving PPIs, the median proportion with hypomagnesaemia was 27.1% (range 11.3-55.2%), compared to 18.4% (4.3-52.7%) in patients not receiving PPIs. A pooled odds ratio for PPI use was 1.775 (95% confidence interval 1.077-2.924) in patients with hypomagnesaemia; however, there was significant heterogeneity in the included studies (Cochran's Q test, P < 0.001).
This meta-analysis provides support for the notion of PPI-induced hypomagnesaemia; however, a definitive conclusion cannot be drawn due to the heterogeneity of the studies included. Prospective cohort studies of PPI use, with regular magnesium monitoring, are needed to address this. Obesity is associated with hypertension, diabetes mellitus and the onset of heart failure (HF). The complex relationship between obesity and HF is poorly understood. Obesity is associated with alteration to myocardial contractility and cardiac remodelling. A total of 9507 subjects enrolled in the Atherosclerosis Risk in Communities study were studied. Patients with severe obesity (n ¼ 1141), defined as body mass index (BMI) > 35 kg/m 2 , were more likely to have measurable high sensitivity cardiac troponin T (hs-cTnT) than individuals with normal BMI (70% vs. 60%, p < 0.001). The majority was in the range 3-14 ng/L, below the 99th percentile cut-off of 14 ng/L; however, 9% were above 14 ng/L in severely obese subjects. Concentrations >14 ng/L were associated with severe obesity, even after adjusting for traditional risk factors (odds ratio 2.20, 95% CI 1.59 to 3.06). Over 12-year follow up, HF occurred in 869 subjects. Severe obesity and elevated hs-cTnT were associated with a nine-fold higher risk of HF than subjects with normal weight and undetectable hs-cTnT.
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This article highlights the serious clinical problem of severe obesity beyond that of associated risk factors. The utilisation of cTnT measurement identifies patients with subclinical cardiac cell damage. This adds further to the use of sensitive cardiac troponins as risk markers rather than a subtle event marker. 
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